Literature DB >> 3484563

Management of spasmodic torticollis.

H J Colbassani, J H Wood.   

Abstract

Based on a review of the literature, the management of spasmodic torticollis may begin with the conservative measures of pharmacotherapy, sensory feedback, or percutaneous dorsal column stimulation. Approximately 50% of patients will benefit from an adequate trial of these modalities. With particularly resistant and disabling torticollis, the ablative procedures of microsurgical cervical rhizotomy or stereotaxic thalamotomy have offered significant relief in about 74% and 56%, respectively, of properly selected cases. Nevertheless, the variability in the duration of response to all forms of therapy has made the treatment of spasmodic torticollis a difficult and often frustrating undertaking.

Entities:  

Mesh:

Year:  1986        PMID: 3484563     DOI: 10.1016/0090-3019(86)90285-5

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  6 in total

1.  Long-term outcome after surgery for spasmodic torticollis.

Authors:  J Hernesniemi; T Keränen
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation.

Authors:  A Münchau; C D Good; S McGowan; N P Quinn; J D Palmer; K P Bhatia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-07       Impact factor: 10.154

Review 3.  The use of thalamotomy in the treatment of levodopa-induced dyskinesia.

Authors:  R D Page
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

4.  Microvascular decompression for spasmodic torticollis.

Authors:  H D Jho; P J Jannetta
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Symptomatic and functional outcome of surgical treatment of cervical dystonia.

Authors:  J K Krauss; E G Toups; J Jankovic; R G Grossman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

6.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.